Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".

Anne LecoutourClaire DupontDominique CaldariClémentine DumantAudrey VanrenterghemMathias RuizRémi Duclaux-LorasStéphanie BerthetGeorges DimitrovDelphine LacroixPauline DuvantCéline RomanAnne Claire WagnerAurélie BourmaudJérôme VialaFrank M RuemmeleBénédicte Pigneurnull null

Published in: Journal of pediatric gastroenterology and nutrition (2024)

IFX is effective in maintaining remission at 1 year in pediatric CD patients experiencing a LOR or intolerance with ADA, and IFX could be an interesting therapeutic choice instead of other biologics in this situation.

Keyphrases

ulcerative colitis
newly diagnosed
rheumatoid arthritis
clinical trial
cross sectional
disease activity
systemic lupus erythematosus
patient reported outcomes
decision making
childhood cancer